Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer

Jean Marc Classe; Olivier Glehen; Evelyne Decullier; Jean Marc Bereder; Simon Msika; Gérard Lorimier; Karine Abboud; Pierre Meeus; Gwenael Ferron; François Quenet; Frederic Marchal; Sebastien Gouy; Christophe Pomel; Marc Pocard; Frederic Guyon; Naoual Bakrin

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer

Jean Marc Classe, Olivier Glehen, Evelyne Decullier, Jean Marc Bereder, Simon Msika, Gérard Lorimier, Karine Abboud, Pierre Meeus, Gwenael Ferron, François Quenet, Frederic Marchal, Sebastien Gouy, Christophe Pomel, Marc Pocard, Frederic Guyon, Naoual Bakrin

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

36 Citations (Scopus)

Résumé

Background: To assess impact of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients treated for a first relapse of ovarian cancer (FROC). Patients and Methods: Patients with a FROC treated with second-line chemotherapy, surgery and HIPEC were retrospectively included from 13 Institutions. Studied parameters were interval free between the end of initial treatment and the first relapse, second-line chemotherapy, peritoneal cancer index and completeness of surgery, HIPEC, mortality and morbidity, pathological results and survival. Results: From 2001 to 2010, 314 patients were included. The main strategy was secondary chemotherapy followed by surgery and HIPEC (269/314- 85.6%). Mortality and morbidity rates were respectively 1% and 30.9%. Median follow-up was 50 months, 5-year overall survival was 38.0%, with no difference between platinum-sensitive or -resistant patients and 5-year disease-free survival was 14%. Conclusion: HIPEC allows encouraging survival in the treatment of FROC, better in case of complete surgery, with acceptable mortality and morbidity rates.

langue originale	Anglais
Pages (de - à)	4997-5006
Nombre de pages	10
journal	Anticancer Research
Volume	35
Numéro de publication	9
état	Publié - 1 sept. 2015

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{8da258af964043bf96b4061db4a26dee,

title = "Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer",

abstract = "Background: To assess impact of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients treated for a first relapse of ovarian cancer (FROC). Patients and Methods: Patients with a FROC treated with second-line chemotherapy, surgery and HIPEC were retrospectively included from 13 Institutions. Studied parameters were interval free between the end of initial treatment and the first relapse, second-line chemotherapy, peritoneal cancer index and completeness of surgery, HIPEC, mortality and morbidity, pathological results and survival. Results: From 2001 to 2010, 314 patients were included. The main strategy was secondary chemotherapy followed by surgery and HIPEC (269/314- 85.6%). Mortality and morbidity rates were respectively 1% and 30.9%. Median follow-up was 50 months, 5-year overall survival was 38.0%, with no difference between platinum-sensitive or -resistant patients and 5-year disease-free survival was 14%. Conclusion: HIPEC allows encouraging survival in the treatment of FROC, better in case of complete surgery, with acceptable mortality and morbidity rates.",

keywords = "Hyperthermic intra-peritoneal chemotherapy, Ovarian cancer relapse, Secondary surgery",

author = "Classe, {Jean Marc} and Olivier Glehen and Evelyne Decullier and {Marc Bereder}, Jean and Simon Msika and G{\'e}rard Lorimier and Karine Abboud and Pierre Meeus and Gwenael Ferron and Fran{\c c}ois Quenet and Frederic Marchal and Sebastien Gouy and Christophe Pomel and Marc Pocard and Frederic Guyon and Naoual Bakrin",

year = "2015",

month = sep,

day = "1",

language = "English",

volume = "35",

pages = "4997--5006",

journal = "Anticancer Research",

issn = "0250-7005",

number = "9",

}

TY - JOUR

T1 - Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer

AU - Classe, Jean Marc

AU - Glehen, Olivier

AU - Decullier, Evelyne

AU - Marc Bereder, Jean

AU - Msika, Simon

AU - Lorimier, Gérard

AU - Abboud, Karine

AU - Meeus, Pierre

AU - Ferron, Gwenael

AU - Quenet, François

AU - Marchal, Frederic

AU - Gouy, Sebastien

AU - Pomel, Christophe

AU - Pocard, Marc

AU - Guyon, Frederic

AU - Bakrin, Naoual

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background: To assess impact of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients treated for a first relapse of ovarian cancer (FROC). Patients and Methods: Patients with a FROC treated with second-line chemotherapy, surgery and HIPEC were retrospectively included from 13 Institutions. Studied parameters were interval free between the end of initial treatment and the first relapse, second-line chemotherapy, peritoneal cancer index and completeness of surgery, HIPEC, mortality and morbidity, pathological results and survival. Results: From 2001 to 2010, 314 patients were included. The main strategy was secondary chemotherapy followed by surgery and HIPEC (269/314- 85.6%). Mortality and morbidity rates were respectively 1% and 30.9%. Median follow-up was 50 months, 5-year overall survival was 38.0%, with no difference between platinum-sensitive or -resistant patients and 5-year disease-free survival was 14%. Conclusion: HIPEC allows encouraging survival in the treatment of FROC, better in case of complete surgery, with acceptable mortality and morbidity rates.

AB - Background: To assess impact of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients treated for a first relapse of ovarian cancer (FROC). Patients and Methods: Patients with a FROC treated with second-line chemotherapy, surgery and HIPEC were retrospectively included from 13 Institutions. Studied parameters were interval free between the end of initial treatment and the first relapse, second-line chemotherapy, peritoneal cancer index and completeness of surgery, HIPEC, mortality and morbidity, pathological results and survival. Results: From 2001 to 2010, 314 patients were included. The main strategy was secondary chemotherapy followed by surgery and HIPEC (269/314- 85.6%). Mortality and morbidity rates were respectively 1% and 30.9%. Median follow-up was 50 months, 5-year overall survival was 38.0%, with no difference between platinum-sensitive or -resistant patients and 5-year disease-free survival was 14%. Conclusion: HIPEC allows encouraging survival in the treatment of FROC, better in case of complete surgery, with acceptable mortality and morbidity rates.

KW - Hyperthermic intra-peritoneal chemotherapy

KW - Ovarian cancer relapse

KW - Secondary surgery

UR - http://www.scopus.com/inward/record.url?scp=84939634440&partnerID=8YFLogxK

M3 - Article

C2 - 26254399

AN - SCOPUS:84939634440

SN - 0250-7005

VL - 35

SP - 4997

EP - 5006

JO - Anticancer Research

JF - Anticancer Research

IS - 9

ER -